Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial
NCT ID NCT06068530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether giving entire communities antimalarial drugs along with a malaria vaccine can reduce the spread of the disease better than drugs alone, vaccine alone, or no extra intervention. About 10,000 people aged 6 months and older in malaria-prone villages will take part. The goal is to see if this combined approach lowers malaria cases and infections over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dihydroartemisinin/piperaquine and single low-dose primaquine (antimalarial drugs) plus R21/Matrix-M malaria vaccine
What this could lead to
If successful, this could show that combining mass drug administration with vaccination is a powerful way to reduce malaria transmission and save lives.
What could go wrong
This is a large trial, but results may vary by region and the approach may be logistically challenging. There are also risks of side effects from the drugs or vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alikadam Upazila Health Complex
RECRUITINGBāndarban, 4650, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lama Upazila Health Complex
RECRUITINGLāma, 4641, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••